Description
CJC-1295 (DAC) is a modified growth hormone-releasing hormone analogue incorporating a Drug Affinity Complex designed to extend systemic exposure through albumin binding. It is investigated for sustained growth-hormone axis signaling. The exact linker, counterion, purity, identity, aggregation profile and lot-specific stability require qualified analytical confirmation.
| Mechanism of Action | Primary Research Applications | CAS Number | Molecular Formula | Molecular Weight (g/mol) | IUPAC / Sequence Definition | Material Class | Form / Apperance |
| GHRH receptor agonism with extended albumin-associated exposure | Growth-hormone axis and endocrine signaling research | 863288-34-0 | C152H252N44O42 | 3367.97 | Modified GRF(1-29) with Drug Affinity Complex linker | Modified peptide | White to off-white lyophilized cake/powder |
| Combined prolonged GHRH receptor and ghrelin receptor agonism | Growth-hormone axis and secretagogue pathway research | Not applicable | Mixture | CJC-1295 with DAC + Ipamorelin; component ratios must be specified | Blend | White to off-white lyophilized cake/powder |

